| Cat. No. |
Product Name |
Information |
| PC-49121 |
Becotatug
Anti-EGFR
|
Becotatug is a humanized monoclonal antibody against EGFR (ERRBB1). Isotype: IgG1-kappa, Anti-[human EGFR (epidermal growth factor receptor, receptor tyrosineprotein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody. |
| PC-49119 |
Atisnolerbart
Anti-Bet V1
|
Atisnolerbart is a monoclonal antibody directed against Bet v 1 allergen (Betula alleghaniensis (yellow birch) pollen allergen 1). Isotype: IgG4-kappa, Anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1], human monoclonal antibody. |
| PC-49118 |
Anzurstobart
Anti-SIRPα
|
Anzurstobart (BMS-986351, CC 95251) is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα). Isotype:IgG1-kappa, Anti-[Human SIRPA
(signal regulatory protein alpha, SHPS1, protein tyrosine phosphatase non-receptor type substrate 1, PTPNS1, SIRP, SIRP alpha, CD172a)], human monoclonal antibody. |
| PC-38910 |
Anselamimab
Anti-Serum Amyloid A mAb
|
Anselamimab (CAEL-101) is monoclonal antibody against serum amyloid A, directly targets human light-chain amyloid deposits and affects their removal via a phagocyte-mediated response, shows potential amyloidolytic effect. |
| PC-38887 |
Zansecimab
Anti-ANGPT2 mAb
|
Zansecimab (LY3127804) is a humanized IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2), neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. |
| PC-38886 |
Olokizumab
Anti-IL-6 mAb
|
Olokizumab is a humanized antibody targeting interleukin-6 (IL-6), binds to IL-6 at Site 3 and neutralizes biological activity through blocking hexamer formation on the gp130 signaling axis. |
| PC-38885 |
Tamtuvetmab
Anti-Canine CD52 mAb
|
Tamtuvetmab is a recombinantchimeric (dog/rat) monoclonal antibody against CD52, with potential in the treatment of veterinary antineoplastic. |
| PC-38884 |
Blontuvetmab
Anti-MS4A1 (CD20) mAb
|
Blontuvetmab is a caninized monoclonal antibody that targets MS4A1/CD20, can be potentially used in the treatment of Canine B-cell lymphoma. |
| PC-38881 |
Narsoplimab
Anti-MASP2 mAb
|
Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. |
| PC-38880 |
Ranevetmab
Anti-Canine NGF mAb
|
Ranevetmab is a caninized monoclonal antibody that targets nerve-growth factor (NGF), can be potentially used in the treatment of osteoarthritis (OA). |
| PC-38874 |
Zimberelimab
Anti-PD-1 mAb
|
GLS-010 (Zimberelimab, AB122) is a fully human, monoclonal immunoglobulin G4 (IgG4) anti-programmed death-1 (PD-1) antibody that shows promising efficacy and safety in advanced solid tumors. |
| PC-38873 |
Vudalimab
PD-1/CTLA-4 bispecific mAb
|
Vudalimab (XmAb 20717, XmAb 717) is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. |
